Lb Pharmaceuticals (LBRX) Enterprise Value (2024 - 2026)

Lb Pharmaceuticals' Enterprise Value history runs 3 years deep, the most recent figure standing at -$365.6 million for Q1 2026.

• On a quarterly basis, Enterprise Value changed N/A year-over-year to -$365.6 million in Q1 2026; TTM through Mar 2026 was -$365.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$295.2 million, down 954.37% from the prior year.
• Enterprise Value fell to -$365.6 million in Q1 2026 per LBRX's latest filing, from -$295.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$28.0 million in Q4 2024 and bottomed at -$365.6 million in Q1 2026.
• The 3-year median for Enterprise Value is -$304.8 million (2025), against an average of -$250.8 million.
• Biggest YoY gain for Enterprise Value was 954.37% in 2025; the steepest drop was 954.37% in 2025.
• Year by year, Enterprise Value stood at -$28.0 million in 2024, then tumbled by 954.37% to -$295.2 million in 2025, then declined by 23.85% to -$365.6 million in 2026.
• Per Business Quant, the three latest LBRX Enterprise Value figures stand at -$365.6 million (Q1 2026), -$295.2 million (Q4 2025), and -$314.5 million (Q3 2025).